Medicare Enrolled
Dr. Arsh Singh, M.D.
Hematology · Port Charlotte, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Singh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Singh? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Singh
Dr. Arsh Singh is a hematology in Port Charlotte, FL, with 15 years in practice. Based on federal Medicare data, Dr. Singh performed 244,986 Medicare services across 6,795 unique beneficiaries.
Between the years covered by Open Payments, Dr. Singh received a total of $5,279 from 59 pharmaceutical and/or device companies across 264 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Singh is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice▲ Top 13% volume in FL$ $5,279 industry payments
Medicare Practice Summary
Medicare Utilization ↗244,986
Medicare services
Top 13% in FL for hematology
6,795
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~16,332 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 57,630 | $0 | $4 |
| Iron sucrose injection (Venofer) | 34,100 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 18,800 | $42 | $137 |
| Filgrastim injection (Zarxio) for white blood cells | 17,580 | $0 | $2 |
| Nivolumab injection (Opdivo) | 16,160 | $24 | $72 |
| Anti-nausea injection (aprepitant) | 15,080 | $1 | $5 |
| Oxaliplatin chemotherapy injection | 10,400 | $0 | $12 |
| Paclitaxel chemotherapy injection | 9,856 | $0 | $2 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 8,340 | $1 | $3 |
| Epoetin alfa injection (Procrit) for anemia | 7,378 | $6 | $23 |
| Injection, mepolizumab, 1 mg | 5,700 | $23 | $72 |
| Denosumab injection (Prolia/Xgeva) | 5,400 | $18 | $51 |
| Daratumumab injection (Darzalex) | 4,860 | $38 | $110 |
| Injection, eflapegrastim-xnst, 0.1 mg | 4,620 | $26 | $116 |
| Dexamethasone injection (steroid) | 3,247 | $0 | $3 |
| Immune globulin infusion (Gammagard) | 3,094 | $36 | $108 |
| Complete blood count (CBC) with differential | 2,812 | $8 | $29 |
| Blood draw (venipuncture) | 2,739 | $8 | $9 |
| Injection, bortezomib, 0.1 mg | 2,100 | $3 | $113 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,690 | $1 | $28 |
| Infliximab infusion (Remicade) | 1,070 | $27 | $124 |
| Injection of additional new drug or substance into vein | 1,001 | $12 | $61 |
| Office visit, established patient (30-39 min) | 955 | $96 | $339 |
| Drug injection, under skin or into muscle | 903 | $11 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 884 | $0 | $9 |
| Injection, leucovorin calcium, per 50 mg | 755 | $3 | $12 |
| Injection, etoposide, 10 mg | 619 | $1 | $18 |
| Administration of chemotherapy into vein, 1 hour or less | 616 | $97 | $378 |
| Injection, fulvestrant, 25 mg | 580 | $8 | $132 |
| Injection, fluorouracil, 500 mg | 507 | $2 | $7 |
| Office visit, established patient (20-29 min) | 495 | $66 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 483 | $48 | $189 |
| Injection, carboplatin, 50 mg | 291 | $2 | $41 |
| Injection, potassium chloride, per 2 meq | 285 | $0 | $4 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 276 | $17 | $59 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 235 | $1 | $6 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 229 | $3 | $205 |
| Injection, diphenhydramine hcl, up to 50 mg | 218 | $1 | $3 |
| Administration of chemotherapy into vein, each additional hour | 216 | $21 | $79 |
| Injection, magnesium sulfate, per 500 mg | 212 | $1 | $2 |
| Injection, cisplatin, powder or solution, 10 mg | 210 | $2 | $13 |
| Red blood count, automated test | 189 | $4 | $10 |
| Infusion into a vein for hydration, each additional hour | 177 | $10 | $42 |
| Infusion, normal saline solution , 1000 cc | 173 | $2 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 170 | $49 | $178 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 164 | $3 | $11 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 141 | $55 | $206 |
| New patient office visit, complex (60-74 min) | 127 | $165 | $585 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 120 | $16 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 107 | $22 | $84 |
| Infusion into a vein for hydration, 31-60 minutes | 97 | $25 | $156 |
| Injection of drug or substance into vein | 97 | $28 | $156 |
| Prothrombin time test (blood clotting) | 85 | $4 | $15 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 85 | $136 | $562 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 81 | $25 | $89 |
| Automated urinalysis | 76 | $2 | $8 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 60 | $128 | $637 |
| Administration of additional new drug or substance into vein using push technique | 57 | $42 | $170 |
| Hospital follow-up visit, moderate complexity | 53 | $62 | $197 |
| Office visit, established patient, complex (40-54 min) | 48 | $137 | $474 |
| Initial hospital admission, high complexity | 41 | $134 | $556 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 40 | $15 | $56 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 37 | $1 | $7 |
| New patient office visit (45-59 min) | 35 | $115 | $453 |
| Drawing of blood for a medical problem | 30 | $66 | $277 |
| Office visit, established patient (10-19 min) | 29 | $42 | $147 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 16 | $4 | $15 |
| Transitional care management services for problem of at least moderate complexity | 14 | $158 | $533 |
| Transitional care management services for problem of high complexity | 11 | $214 | $722 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
25.8% high complexity
70.8% medium
3.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,279
Total received (2018-2024)
Avg $754/year across 7 years
Bottom 42% in FL for hematology
59
Companies
264
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,058 (95.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$221 (4.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,909
2023$1,051
2022$781
2021$695
2020$655
2019$56
2018$131
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$659
Merck Sharp & Dohme LLC
$283
Novartis Pharmaceuticals Corporation
$282
E.R. Squibb & Sons, L.L.C.
$263
Daiichi Sankyo Inc.
$240
Gilead Sciences, Inc.
$237
Celgene Corporation
$223
Merck Sharp & Dohme Corporation
$214
BeiGene USA, Inc.
$197
Takeda Pharmaceuticals U.S.A., Inc.
$179
Lilly USA, LLC
$166
PFIZER INC.
$156
Seagen Inc.
$150
Incyte Corporation
$143
Astellas Pharma US Inc
$140
AstraZeneca Pharmaceuticals LP
$124
ARRAY BIOPHARMA INC
$110
EMD Serono, Inc.
$103
GENZYME CORPORATION
$102
GlaxoSmithKline, LLC.
$91
Exelixis Inc.
$84
Ipsen Biopharmaceuticals, Inc
$77
SOBI, INC
$70
Regeneron Healthcare Solutions, Inc.
$67
PharmaEssentia USA Corporation
$55
Pharmacosmos Therapeutics Inc.
$53
Bayer Healthcare Pharmaceuticals Inc.
$50
Myovant Sciences Inc.
$48
Kite Pharma, Inc.
$47
Sumitomo Pharma America, Inc.
$45
Foundation Medicine, Inc.
$42
AbbVie Inc.
$40
Genentech USA, Inc.
$37
ABBVIE INC.
$31
Jazz Pharmaceuticals Inc.
$26
Spectrum Pharmaceuticals Inc.
$26
Telix Pharmaceuticals
$25
JAZZ PHARMACEUTICALS INC.
$24
Alexion Pharmaceuticals, Inc.
$23
GE HealthCare
$22
Acrotech Biopharma Inc.
$22
Pharmacyclics LLC, An AbbVie Company
$22
Kyowa Kirin, Inc.
$21
MorphoSys, US Inc.
$20
RECORDATI_RARE_DISEASES_INC.
$20
Apellis Pharmaceuticals, Inc.
$20
Dova Pharmaceuticals
$20
Acceleron Pharma, Inc.
$18
Dendreon Pharmaceuticals LLC
$18
Stemline Therapeutics Inc.
$18
Amgen Inc.
$17
G1 Therapeutics, Inc.
$16
Horizon Pharma plc
$15
NOVARTIS PHARMACEUTICALS CORPORATION
$14
TAIHO ONCOLOGY, INC.
$14
Acrotech Biopharma LLC
$14
Genmab U.S., Inc.
$13
SANOFI-AVENTIS U.S. LLC
$13
Epizyme, Inc.,
$12
Top 3 companies account for 23.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · Alecensa · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · DARZALEX · DOPTELET · Doptelet · ELITEK · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · FOUNDATIONONE · FRUZAQLA · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JAYPIRCA · KEYTRUDA · KISQALI · KRYSTEXXA · LIBTAYO · LONSURF · LUMAKRAS · MONJUVI · MONOFERRIC · NINLARO · Nubeqa · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Padcev · Pomalyst · REBLOZYL · ROLVEDON · RYBREVANT · Reblozyl · SARCLISA · SCEMBLIX · SHINGRIX · SYLVANT · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TIVDAK · TUKYSA · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · XALKORI · XOSPATA · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
10
Per 100K population
5.1
County median income
$66,154
Nearest hospital
Adventhealth Port Charlotte
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Singh is a mixed practice specialist, with above-average Medicare volume (top 13% in FL), and low-engagement industry engagement, with 15 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Singh experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Singh performed 57,630 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Singh receive payments from pharmaceutical companies?
Yes. Dr. Singh received a total of $5,279 from 59 companies across 264 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Singh's costs compare to other hematologys in Port Charlotte?
Dr. Singh's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Singh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Port Charlotte
Browse hematologys in Port Charlotte ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology